Exploring Deception in Antidepressant Trials
Author Information
Author(s): Christopher F Dowrick, John G Hughes, Julia J Hiscock, Mark Wigglesworth, Thomas J Walley
Primary Institution: University of Liverpool
Hypothesis
What are the views of potential participants on the ethics and pragmatics of introducing deception into antidepressant drug trials?
Conclusion
Introducing elements of deception into antidepressant drug trials poses significant ethical and practical challenges, making such designs unlikely to be feasible.
Supporting Evidence
- Participants generally accepted the need for alternative research approaches to antidepressants.
- Concerns were raised about the welfare of patients in deceptive trials.
- Many participants did not view deception as intrinsically unacceptable.
- Authorised deception was the most commonly accepted strategy among participants.
- Minimised deception was considered acceptable by many, but wording was crucial.
Takeaway
The study asked doctors and patients if it's okay to trick people in antidepressant trials. They found that while some tricks might be okay, many people are worried about trust and ethics.
Methodology
Qualitative approach using focus groups and in-depth interviews with general practitioners, psychiatrists, and patients.
Potential Biases
Potential bias in participant selection as those who agreed to participate may have had specific views on antidepressants.
Limitations
The study may not represent all views as participants were recruited from a specific locality and those with a particular interest in the subject.
Participant Demographics
Participants included 27 general practitioners, 15 psychiatrists, and 6 patients, with a mix of genders and experiences with depression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website